The aesthetic neurotoxin market is mature and competitive, where differentiation comes from formulation and duration rather than mechanism. Daxxify (daxibotulinumtoxinA) entered on both counts.
It temporarily blocks acetylcholine release at the neuromuscular junction, and unlike other formulations it uses a proprietary stabilizing peptide instead of human serum albumin. The injectable toxin treats moderate-to-severe glabellar lines associated with corrugator or procerus muscle activity in adults.
Daxxify has since added a cervical dystonia indication, extending it into therapeutic use alongside aesthetics. Its duration claim is the principal competitive lever against entrenched incumbents, with the albumin-free formulation as a secondary differentiator worth tracking.
